Innovating Works

ARTHEX BIOTECH

Activa
ENTRY-DM: Interdisciplinary doctoral training on oligonucleotide based therapies for myotonic dystrophy Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of d...
2024-06-28 - 2029-02-28 | Financiado
fight-dm1: First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1) ARTHEX BIOTECH tramitó un HORIZON EUROPE: HORIZON-EIC-2022-ACCELERATOR-01 Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide...
2022-12-21 - 2025-06-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.